Stock Analysis, Dividends, Split History

NWBO / Northwest Biotherapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)103.03
Enterprise Value ($M)128.01
Book Value ($M)-84.30
Book Value / Share-0.19
Price / Book-1.22
NCAV ($M)-109.83
NCAV / Share-0.25
Price / NCAV-0.94
Share Statistics
Common Stock Shares Outstanding 328,900,000
Common Shares Outstanding 414,665,188
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)2.04
Return on Assets (ROA)-1.38
Return on Equity (ROE)2.76
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio0.02
Income Statement (mra) ($M)
Sales Revenue Goods Net0.00
Sales Revenue Net336,000.00
Revenue From Grants336,000.00
Operating Income-54.68
Net Income-73.14
Earnings Per Share Diluted-0.31
Earnings Per Share Basic And Diluted-0.31
Earnings Per Share Basic-0.31
Cash Flow Statement (mra) ($M)
Cash From Operations-36.49
Cash from Investing0.21
Cash from Financing0.21
Identifiers and Descriptors
Central Index Key (CIK)1072379
Related CUSIPS
66737P900 66737P950

Split History

Stock splits are used by Northwest Biotherapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
NWBO : Northwest Biotherapeutics Stock Analysis and Research Report

2017-11-11 - Asif

The Company is focused on developing personalized immune therapies for cancer. Northwest Biotherapeutics has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company’s lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. This product in an ongoing Phase III trial for newly diagnosed Glioblastome multiforme (GBM). 331 patients have been enrolled in the trial, and enrollment is closed. The Company is continuing to collect data “events” in the Phase III trial, and the data set is gradually maturing. The Company is also working on preparations for Phase II trials of DCVax-L for other indications. The Company’s second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed, and included treatment of a diverse range of cancers. The Company is working on preparations for P...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

2018-06-06 seekingalpha
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors. (299-6)

Northwest Bio's Big Data Change The Game

2018-06-03 seekingalpha
Note: This article was written several days ago and published on Avisol Capital Partners's Total Pharma Tracker, a marketplace service dedicated to helping investors sift through the noise and find biotech gems. Become a trial subscriber for free today! (25-2)

CUSIP: 66737P600